{"id":"https://genegraph.clinicalgenome.org/r/b07062ee-2333-4a11-8fa1-ad33ff933ee1v1.0","type":"EvidenceStrengthAssertion","dc:description":"","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/b07062ee-2333-4a11-8fa1-ad33ff933ee1","GCISnapshot":"https://genegraph.clinicalgenome.org/r/77dd197b-f374-4c50-be77-7aba619e80aa","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/77dd197b-f374-4c50-be77-7aba619e80aa_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10010","date":"2020-09-01T00:00:00Z","role":"Unpublisher"},{"id":"https://genegraph.clinicalgenome.org/r/fb987774-0e5b-4466-924f-6f19fccc6599_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10010","date":"2020-09-01T00:00:00Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/fb987774-0e5b-4466-924f-6f19fccc6599_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10010","date":"2018-01-23T17:00:00.000Z","role":"Approver"}],"curationReasonDescription":"","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fb987774-0e5b-4466-924f-6f19fccc6599_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c6018aac-e429-454a-9a61-e9eb0799d209_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This variant accounts for ~67% of mutant ACADM alleles (Matern and Rinaldo, 2015).  Functional studies suggest that the variant results in reduced enzyme activity (Sturm et al. 2012). The variant is reported to cause protein misfolding (Fernandez-Guerra et al. 2014).","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/259af158-9e8f-4a4e-99ff-5f6311865241","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1972503","rdfs:label":"Patient III","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"The entire coding region of MCAD cDNA was synthesized from mRNA of patient fibroblast culture, PCR amplified, cloned, and sequenced.","phenotypeFreeText":"No information on specific phenotypes.","previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/c6018aac-e429-454a-9a61-e9eb0799d209_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1972503","allele":{"id":"https://genegraph.clinicalgenome.org/r/4a44fa4d-1e10-4f51-8aec-51c513c1126e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001127328.2(ACADM):c.997A>G (p.Lys333Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/3586"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/a182a176-8fc4-407e-a17d-f4c92827fc6c_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This variant accounts for ~67% of mutant ACADM alleles (Matern and Rinaldo, 2015).  Functional studies suggest that the variant results in reduced enzyme activity (Sturm et al. 2012). The variant is reported to cause protein misfolding (Fernandez-Guerra et al. 2014).","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d5ac290a-3e26-41ba-bb46-5aa00e7c742d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18241067","rdfs:label":"Infant 22","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"See group info.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypeFreeText":"Dx by physician treatment center physician with MCADD by plasma acylcarnitine profile and urine acylglycines and organic acid studies. C8 = 39.2 umol/L","previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/a182a176-8fc4-407e-a17d-f4c92827fc6c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18241067","allele":{"id":"https://genegraph.clinicalgenome.org/r/4a44fa4d-1e10-4f51-8aec-51c513c1126e"}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/094eb021-32fa-438f-9926-fea625c325c7_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Functional evidence: expression in E. coli showed decreased MCAD enzyme activity (Andresen, 2001).","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fe02a599-139f-41bc-b7a1-be4f3b56e74b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18241067","rdfs:label":"Infant 2","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"See group info.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypeFreeText":"Dx by physician treatment center physician with MCADD by plasma acylcarnitine profile and urine acylglycines and organic acid studies. C8 = 0.9umol/L","previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/094eb021-32fa-438f-9926-fea625c325c7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18241067","allele":{"id":"https://genegraph.clinicalgenome.org/r/5b951c4a-83d2-4c8c-91ae-46abb0e6943a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000016.5(ACADM):c.362C>T (p.Thr121Ile)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/3599"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/d9fd3974-01b9-4ad7-9bfb-c9299a6fa13f_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This variant accounts for ~67% of mutant ACADM alleles.  Functional studies suggest that the variant results in reduced enzyme activity (Sturm et al. 2012). The variant is reported to cause protein misfolding (Fernandez-Guerra et al. 2014).","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3f61a7ee-76fc-4f79-8524-9a8e2066d4a8","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1972503","rdfs:label":"Patient I","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"The entire coding region of MCAD cDNA was synthesized from mRNA of patient fibroblast culture, PCR amplified, cloned, and sequenced.","phenotypeFreeText":"No information on specific phenotypes.","previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/d9fd3974-01b9-4ad7-9bfb-c9299a6fa13f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1972503","allele":{"id":"https://genegraph.clinicalgenome.org/r/4a44fa4d-1e10-4f51-8aec-51c513c1126e"}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/7975012c-6360-4878-835e-e26c75c8624a_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This variant accounts for ~67% of mutant ACADM alleles (Matern and Rinaldo, 2015).  Functional studies suggest that the variant results in reduced enzyme activity (Sturm et al. 2012). The variant is reported to cause protein misfolding (Fernandez-Guerra et al. 2014).","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/61262285-a97e-4554-8bd9-effde01ab5bc","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18241067","rdfs:label":"Infant 21","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"See group info.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypeFreeText":"Dx by physician treatment center physician with MCADD by plasma acylcarnitine profile and urine acylglycines and organic acid studies. C8 = 26.4 umol/L","previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/7975012c-6360-4878-835e-e26c75c8624a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18241067","allele":{"id":"https://genegraph.clinicalgenome.org/r/4a44fa4d-1e10-4f51-8aec-51c513c1126e"}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/6af74d8e-91eb-43a2-8c33-9671117b0918_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This variant accounts for ~67% of mutant ACADM alleles (Matern and Rinaldo, 2015).  Functional studies suggest that the variant results in reduced enzyme activity (Sturm et al. 2012). The variant is reported to cause protein misfolding (Fernandez-Guerra et al. 2014).","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a64a43f0-7ead-4622-b9a5-802ec049768c","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18241067","rdfs:label":"Infant 19","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"See group info.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypeFreeText":"Dx by physician treatment center physician with MCADD by plasma acylcarnitine profile and urine acylglycines and organic acid studies. C8 = 20.5 umol/L","previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/6af74d8e-91eb-43a2-8c33-9671117b0918_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18241067","allele":{"id":"https://genegraph.clinicalgenome.org/r/4a44fa4d-1e10-4f51-8aec-51c513c1126e"}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/c3fdf43e-96e5-4281-a5a9-b094ef1d84c3_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This variant accounts for ~67% of mutant ACADM alleles (Matern and Rinaldo, 2015).  Functional studies suggest that the variant results in reduced enzyme activity (Sturm et al. 2012). The variant is reported to cause protein misfolding (Fernandez-Guerra et al. 2014).","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e956daf7-a821-4346-999a-7872c1695e92","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18241067","rdfs:label":"Infant 18","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"See group info.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypeFreeText":"Dx by physician treatment center physician with MCADD by plasma acylcarnitine profile and urine acylglycines and organic acid studies. C8 = 16.6 umol/L","previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/c3fdf43e-96e5-4281-a5a9-b094ef1d84c3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18241067","allele":{"id":"https://genegraph.clinicalgenome.org/r/4a44fa4d-1e10-4f51-8aec-51c513c1126e"}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/4f1a2d13-fb7a-40e3-9b9a-dd62243a6b56_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This variant accounts for ~67% of mutant ACADM alleles (Matern and Rinaldo, 2015).  Functional studies suggest that the variant results in reduced enzyme activity (Sturm et al. 2012). The variant is reported to cause protein misfolding (Fernandez-Guerra et al. 2014).","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e90e14d8-e816-4318-ac11-29ef72059e55","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18241067","rdfs:label":"Infant 20","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"See group info.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypeFreeText":"Dx by physician treatment center physician with MCADD by plasma acylcarnitine profile and urine acylglycines and organic acid studies. C8 = 21.8 umol/L","previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/4f1a2d13-fb7a-40e3-9b9a-dd62243a6b56_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18241067","allele":{"id":"https://genegraph.clinicalgenome.org/r/4a44fa4d-1e10-4f51-8aec-51c513c1126e"}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/9a26dada-b05d-4917-b79e-b1e6dc5bfb04_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This variant accounts for ~67% of mutant ACADM alleles (Matern and Rinaldo, 2015).  Functional studies suggest that the variant results in reduced enzyme activity (Sturm et al. 2012). The variant is reported to cause protein misfolding (Fernandez-Guerra et al. 2014).","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cb06f704-32f3-4add-a174-4e02211caf33","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1972503","rdfs:label":"Patient II","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"The entire coding region of MCAD cDNA was synthesized from mRNA of patient fibroblast culture, PCR amplified, cloned, and sequenced.","phenotypeFreeText":"No information on specific phenotypes.","previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/9a26dada-b05d-4917-b79e-b1e6dc5bfb04_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1972503","allele":{"id":"https://genegraph.clinicalgenome.org/r/4a44fa4d-1e10-4f51-8aec-51c513c1126e"}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/f57a06ba-547e-4ff9-82a0-e74fe6fe7e9b_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This variant accounts for ~67% of mutant ACADM alleles (Matern and Rinaldo, 2015).  Functional studies suggest that the variant results in reduced enzyme activity (Sturm et al. 2012). The variant is reported to cause protein misfolding (Fernandez-Guerra et al. 2014).","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8bcfd55b-1463-41f3-9a26-aaaa615754da","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18241067","rdfs:label":"Infant 17","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"See group info.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypeFreeText":"Dx by physician treatment center physician with MCADD by plasma acylcarnitine profile and urine acylglycines and organic acid studies. C8 = 11.2 umol/L","previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/f57a06ba-547e-4ff9-82a0-e74fe6fe7e9b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18241067","allele":{"id":"https://genegraph.clinicalgenome.org/r/4a44fa4d-1e10-4f51-8aec-51c513c1126e"}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/a1505edd-c020-4ef1-9d9b-38ffbe57a463_proband_score_evidence_line","type":"EvidenceLine","dc:description":"p.Lys333Glu variant accounts for ~67% of mutant ACADM alleles (Matern and Rinaldo, 2015).  Functional studies suggest that the variant results in reduced enzyme activity (Sturm et al. 2012). The variant is reported to cause protein misfolding (Fernandez-Guerra et al. 2014). In vitro functional studies for the p.Tyr67His suggest that the p.Tyr71 variant only modestly impact protein function (Hara 2016).","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/590b0a7b-9388-47fe-9a70-0f171f525464","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18241067","rdfs:label":"Infant 24","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"See group info.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypeFreeText":"Dx by physician treatment center physician with MCADD by plasma acylcarnitine profile and urine acylglycines and organic acid studies. C8 = 3.7 umol/L","previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/a1505edd-c020-4ef1-9d9b-38ffbe57a463_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18241067","allele":[{"id":"https://genegraph.clinicalgenome.org/r/e8791874-7e55-4aa1-b321-b45ca475d026","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000016.5(ACADM):c.199T>C (p.Tyr67His)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/3597"}},{"id":"https://genegraph.clinicalgenome.org/r/4a44fa4d-1e10-4f51-8aec-51c513c1126e"}]}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/141e1bbe-d1a0-4485-acba-49a4731c401e_proband_score_evidence_line","type":"EvidenceLine","dc:description":"p.Lys333Glu variant accounts for ~67% of mutant ACADM alleles (Matern and Rinaldo, 2015).  Functional studies suggest that the variant results in reduced enzyme activity (Sturm et al. 2012). The variant is reported to cause protein misfolding (Fernandez-Guerra et al. 2014). In vitro functional studies for the p.Tyr67His suggest that the p.Tyr71 variant only modestly impact protein function (Hara 2016).","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/21007c90-1b98-43ec-ac78-9bbbd650fc63","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18241067","rdfs:label":"Infant 23","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"See group info.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypeFreeText":"Dx by physician treatment center physician with MCADD by plasma acylcarnitine profile and urine acylglycines and organic acid studies. C8 = 2.1 umol/L","previousTesting":false,"previousTestingDescription":"","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/141e1bbe-d1a0-4485-acba-49a4731c401e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18241067","allele":[{"id":"https://genegraph.clinicalgenome.org/r/e8791874-7e55-4aa1-b321-b45ca475d026"},{"id":"https://genegraph.clinicalgenome.org/r/4a44fa4d-1e10-4f51-8aec-51c513c1126e"}]}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/fb987774-0e5b-4466-924f-6f19fccc6599_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fb987774-0e5b-4466-924f-6f19fccc6599_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/567437d7-ffdc-4b51-83e7-984985f3edf7","type":"EvidenceLine","dc:description":"Mouse model recapitulates disease.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6b8e9664-7b14-4df8-9ebc-99c320df1e71","type":"Finding","dc:description":"MCAD -/- mice displayed many characteristics of human MCAD deficiency, including newborn loss, intolerance to cold, biochemical changes in blood, tissues and urine.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16121256","rdfs:label":"MCAD -/- Mice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":3}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/fb987774-0e5b-4466-924f-6f19fccc6599_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/51e9b6df-11df-4be6-8d3f-5184dcd53fff","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cfe745bb-c369-484a-a981-1e79d49271c1","type":"FunctionalAlteration","dc:description":"Oxidation of [I-14C]octanoate was impaired (19% of control) as well as the activity of medium-chain (octanoyl-)acyl-CoA dehydrogenase in the supernatants of sonicated fibroblast mitochondria (5% of control). This paper was the first to confirm that the disease is caused by a defect in this enzyme of the beta-oxidation pathway.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/6857268","rdfs:label":"MCAD deficiency in cells"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/d9483208-f34a-4b49-a104-c1de8ad6d174","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1050a546-afb5-4e5f-9928-032a278a5cd4","type":"FunctionalAlteration","dc:description":"Demonstrated a correlation between octanoyl-CoA oxidation rate in lymphocytes and the clinical outcome.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23028790","rdfs:label":"Range of residual activity"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/fb987774-0e5b-4466-924f-6f19fccc6599_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8030518a-58f5-444a-80ed-d295ee408783","type":"EvidenceLine","dc:description":"This is a well-established disease mechanism.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e84175df-c056-4447-b6cd-57f268011a1e","type":"Finding","dc:description":"Beta-oxidation process involves a series of chain-length-specific enzymes which sequentially remove a molecule of acetyl-CoA per cycle. FAO represents a response to tissue energy depletion when fasting, during illness, and increased activity.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/3968063","rdfs:label":"Ikeda 1985","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":81,"specifiedBy":"GeneValidityCriteria6","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/6h5wiJz1-SU","type":"GeneValidityProposition","disease":"obo:MONDO_0008721","gene":"hgnc:89","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_77dd197b-f374-4c50-be77-7aba619e80aa-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}